Benjamin J. Daverman

Ben joined GTCR in 2008 and is currently a Managing Director of the firm. Prior to joining GTCR, he worked as a Venture Capitalist at Alta Partners, as well as an Investment Banking Associate at JMP Securities and an Analyst in the Mergers & Acquisitions group at J.P. Morgan (formerly Hambrecht & Quist). He holds an MBA from the Wharton School at the University of Pennsylvania and a BA in history magna cum laude from Colgate University. Ben also holds a master’s degree in biotechnology from the School of Applied Sciences & Engineering at the University of Pennsylvania.

Ben is the Co-Head of the Healthcare group at GTCR and currently is a Director of Albany Molecular Research, Antylia Scientific, Corza Health, Maravai LifeSciences and TerSera. Ben was previously a Director of past GTCR investments including Actient Pharmaceuticals, Cord Blood Registry, Crealta Pharmaceuticals, Devicor Medical Products, GeneraMedix, Sterigenics and XIFIN. In addition, Ben was involved in transactions with past GTCR investments ATI Physical Therapy and Graceway Pharmaceuticals.

Ben is active in the community and serves on the executive board of Spark Program, a national non-profit that provides transformative apprenticeships for at-risk middle-school students.